·
Virtual event attended by life sciences industry
professionals aimed at transforming and digitalizing the life sciences industry
in India
·
Innovation-driven event focused on addressing
challenges in pharma, biopharma, medical devices and patient care segments
·
Speakers from Biocon, IPCA, Skanray, Sahajanand
Medical Technologies, Lupin, Agappe Diagnostics, Stryker, Brainsight, COMOFI
Medtech, HCL Technologies and Jamia
Milia Islamia
University shared their
knowledge and know-how
Dassault
Systèmes (Euronext
Paris: #13065, DSY.PA) hosted “The World After: From Things to Life 2020,” a one-of-a-kind virtual conference that
provided in-depth insights into the vast potential of the life sciences
industry in India .
With a deep understanding of the current challenges facing pharmaceutical,
biotech and medical device companies, and the patient care sector, Dassault
Systèmes hosted the event as part of its commitment to help advance the pace of
discovery of new drugs and medicines and deliver holistic, superior patient and
physician-centric experiences.
“The World After - From Things
to Life” focused on transforming and digitalizing the life sciences industry in
India, which is undergoing core shifts in business processes and manufacturing
operations to make it more agile and adaptable, reinventing the value chain,
capitalizing knowledge and strategic planning, adhering to regulatory
frameworks, and introducing futuristic and advanced technological solutions.
Addressing the business
challenges of the life sciences industry, Dassault Systèmes demonstrated the
“License to Cure for Biopharma,” “ONE Lab,” and “Accelerated Device” industry
solution experiences based on the 3DEXPERIENCE platform. In the tracks of
the virtual event, several global and local life sciences industry experts and
startups shared their experiences.
The pharma segment of the event covered topics like
digital continuity in the pharmaceutical industry, revolutionizing the drug
development process with artificial intelligence, design and development of
SARS-CoV-2 main protease inhibitors, optimizing laboratories and leveraging
knowledge to improve time to market.
Pharma and biopharma companies are moving towards
unified platforms that help in drug research and discovery enhancing the
ecosystem- research, development, manufacturing and quality and compliance. “Dassault Systèmes’ solution for quality control labs
greatly reduced data input, transcription, and integrity validation efforts increased the overall productivity
of the lab,” said Ashok Nayak, CIO, IPCA Laboratories.
The patient care segment in
the event discussed “In-Silico in healthcare,” optimizing efficacy and safety
for medical devices, simulation-driven new product development (NPD),
simulation for understanding the functional dynamics of the brain and
therapeutic stimulations using AI. The patient care sector is changing
rapidly with a focus on improving patient outcomes and a shift from
intermittent treatments to a continuous engagement driven by simulation
technologies.
“Multiphysics simulation capabilities have helped in
the indigenous research and development of minimally invasive coronary stent
systems as well as in maximizing their life and performance,” said Dr. Ramanan
Lakshminarayanan, Chief Technology Officer, Sahajanand Medical Technologies.
The medical devices segment
in the event highlighted faster time to market of innovative medical devices,
and key technology solutions adopted in the diagnostics segment. Medical
device manufacturers are moving away from point solutions for mechanical and
electrical design, simulation, product data management (PDM) and technical
communication, and toward integrated product development platforms to introduce
product faster into the market and improve the overall performance and
reliability, which is always the big challenge for them.
“Medical Device manufacturers have to embrace digital
technology to overcome the challenges in the manufacturing, product delivery,
supply chain etc., which used to be an option in the past; now it is a must to
sustain in the market and be innovative,” said Vishwaprasad Alva, Managing
Director, Skanray.